(Q45096975)

9 December 2017

Predictors of virological response to atazanavir in protease inhibitor-experienced patients (English)

1 reference

9 December 2017

0 references

1 reference

11

Vincent Soriano

1 reference

9 December 2017

Ana Barrios

1

1 reference

9 December 2017

Ana Lucía Rendón

2

1 reference

9 December 2017

Oscar Gallego

3

1 reference

9 December 2017

Luz Martín-Carbonero

4

1 reference

9 December 2017

Luisa Valer

5

1 reference

9 December 2017

Pilar Ríos

6

1 reference

9 December 2017

Ivana Maida

7

1 reference

9 December 2017

Teresa García-Benayas

8

1 reference

9 December 2017

Inmaculada Jiménez-Nácher

9

1 reference

9 December 2017

Juan González-Lahoz

10

1 reference

9 December 2017

1 July 2004

1 reference

9 December 2017

1 reference

9 December 2017

5

1 reference

9 December 2017

4

1 reference

9 December 2017

201-205

1 reference

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

9 December 2017

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

High-performance liquid chromatographic method for the simultaneous determination of the six HIV-protease inhibitors and two non-nucleoside reverse transcriptase inhibitors in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

The utility of inhibitory quotients in determining the relative potency of protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2F3HL3-HHBD-WKLR-XELL

10.1310/3HL3-HHBD-WKLR-XELL

21 January 2018

Identifiers

DOI

1 reference

9 December 2017

1 reference